Cancer remains among the top contributors to fatality globally. The year 2018 witnessed 9.5 million deaths caused by cancer among 18.1 million new instances and it is projected that there will be 29.5 million newly diagnosed cancer cases, by 2040, and 16.4 million cancer-related deaths annually , . Thus, more efficient measures should be tackled in prevention, diagnosis, and treatment. Oligonucleotide drugs are among possible different cancer therapies which refer to chains of polynucleic acids that can be either modified or unmodified. These chains contain different functional groups depending on their purpose and origin. Small interfering RNA (siRNA), antisense oligonucleotides (ASO), microRNA (miRNA), aptamer, and CpG oligonucleotides (CpG ODNs) are some of the most studied oligonucleotide therapeutics in recent research. Their mechanism of action could be modifying RNA, altering protein expression, gene silencing, or stimulating the production of desired proteins . A number of oligonucleotide medications have recently received approval from the U.S. Food and Drug Administration (FDA) for the treatment of rare diseases . While there are currently no FDA-approved oligonucleotide anti-cancer agents, there is optimism surrounding multiple research studies that are investigating the use of oligonucleotide therapeutics in cancer treatment and oncology. Cancer treatment faces challenges with restricted efficiency and harmful side effects of conventional drugs. Other challenges include tumor heterogeneity and high mutation rates. Oligonucleotide therapeutics are being recognized as a potentially effective class of drugs, with the ability to target proteins and non-coding RNAs that were previously considered inaccessible. which is not possible with chemotherapy medication. They also offer potential solutions for precision anti-cancer medicine. Clinical trials are underway, with the expectation of reaching the market soon , .